Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if it is possible to treat relapsed or refractory
lymphoid malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic
Lymphocytic Leukemia) with a new type of T cell-based immunotherapy (therapy that uses the
immune system to treat the cancer).